	US 11,866,508 B2
	Anti-mesothelin binding proteins
William Christian Fanslow, III, Normandy Park, WA (US); Carl Kozlosky, Bainbridge Island, WA (US); and Jean Gudas, Fremont, CA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Filed by AMGEN INC., Thousand Oaks, CA (US)
Filed on Jan. 6, 2021, as Appl. No. 17/142,850.
Application 17/142,850 is a continuation of application No. 16/123,827, filed on Sep. 6, 2018, granted, now 10,919,975, issued on Feb. 16, 2021.
Application 16/123,827 is a continuation of application No. 15/141,463, filed on Apr. 28, 2016, granted, now 10,100,121, issued on Oct. 16, 2018.
Application 15/141,463 is a continuation of application No. 13/926,847, filed on Jun. 25, 2013, abandoned.
Claims priority of provisional application 61/789,678, filed on Mar. 15, 2013.
Claims priority of provisional application 61/665,139, filed on Jun. 27, 2012.
Prior Publication US 2021/0380714 A1, Dec. 9, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); C07K 16/30 (2006.01); C07K 16/46 (2006.01); G01N 33/68 (2006.01); C07K 16/28 (2006.01)

CPC C07K 16/30 (2013.01) [C07K 16/28 (2013.01); C07K 16/2809 (2013.01); C07K 16/3046 (2013.01); C07K 16/468 (2013.01); G01N 33/6893 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/622 (2013.01); C07K 2317/72 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/92 (2013.01)]

26 Claims

1. A method of determining if a subject has mesothelin expressing tumor cells, comprising:

contacting a tumor sample from the subject with an antibody, antigen binding protein, or fragment thereof, wherein the antibody, antigen binding protein, or fragment thereof comprises a mesothelin binding domain comprising three heavy chain CDRs and three light chain CDRs with sequences selected from the group consisting of:

a) SEQ ID NOs: 45, 46, and 47 of the heavy chain and SEQ ID NOs: 9, 10, and 11 of the light chain;

b) SEQ ID NOs: 48, 49, and 50 of the heavy chain and SEQ ID NOs: 12, 13, and 14 of the light chain;

c) SEQ ID NOs: 51, 52, and 53 of the heavy chain and SEQ ID NOs: 15, 16, and 17 of the light chain;

d) SEQ ID NOs: 51, 52, and 53 of the heavy chain and SEQ ID NOs: 18, 19, and 20 of the light chain;

e) SEQ ID NOs: 54, 55, and 56 of the heavy chain and SEQ ID NOs: 21, 22, and 23 of the light chain;

f) SEQ ID NOs: 57, 58, and 59 of the heavy chain and SEQ ID NOs: 24, 25, and 26 of the light chain;

g) SEQ ID NOs: 60, 61, and 62 of the heavy chain and SEQ ID NOs: 27, 28, and 29 of the light chain;

h) SEQ ID NOs: 63, 64, and 65 of the heavy chain and SEQ ID NOs: 30, 31, and 32 of the light chain:

i) SEQ ID NOs: 63, 64, and 65 of the heavy chain and SEQ ID NOs: 33, 34, and 35 of the light chain:

j) SEQ ID NOs: 63, 64, and 65 of the heavy chain and SEQ ID NOs: 36, 37, and 38 of the light chain, and

k) any one of (a)-(j), wherein each of the CDRs are identical to or comprise 1, 2, or 3 amino acid residue substitutions relative to their specified sequence; and

detecting binding of the antibody, antigen binding protein, or fragment thereof to the sample, wherein an increase in binding of the antibody, antigen binding protein, or fragment thereof to the sample as compared to binding of the antibody, antigen binding protein, or fragment thereof to a control sample identifies the subject as having mesothelin expressing tumor cells.